Skip to main content
main-content

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Journal of Translational Medicine 1/2014

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)

Zeitschrift:
Journal of Translational Medicine > Sonderheft 1/2014
Autoren:
Igor Puzanov, Grant McArthur, Rene Gonzalez, Anna Pavlick, Omid Hamid, Thomas F Gajewski, Ming Yin, Jill Fredrickson, Nicholas Choong, Antoni Ribas

Without Abstract

Über diesen Artikel

Weitere Artikel der Sonderheft 1/2014

Journal of Translational Medicine 1/2014Zur Ausgabe